Pass RAPS RAC-US Exam with Guarantee Updated 100 Questions
Latest RAC-US Pass Guaranteed Exam Dumps Certification Sample Questions
NEW QUESTION # 21
A global company has obtained a patent in a specific country for a newly marketed product.
What would be the BEST advice In order to protect the patent in other countries?
- A. File design patents in target countries.
- B. Use the community patent system.
- C. Use the Madrid system.
- D. File patents of interest in target countries.
Answer: D
NEW QUESTION # 22
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Follow-up meeting after submission
- B. Frequent communication
- C. Documented agreement
- D. Early collaboration
Answer: B
NEW QUESTION # 23
A company establishes a new medical device indication for its consumer disposable products. The regulatory affairs professional is asked to give a 30-minute training session on these products to sales representatives. Which of the following subjects is the MOST important to discuss?
- A. Labeling
- B. Safety-related reporting
- C. Regulatory application summary
- D. Risk management process
Answer: A
NEW QUESTION # 24
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- B. Wait for the regulatory authority's final publication on its findings.
- C. Contact the regulatory authority to discuss its findings.
- D. Contact the regulatory authority to argue that its conclusions are wrong.
Answer: C
NEW QUESTION # 25
A regulation change is imminent and may require further non-clinical testing on a product currently in Phase III clinical trials. What is the most appropriate action to take FIRST?
- A. Inform the company's senior management and arrange an emergency meeting
- B. Obtain a copy of the proposed regulation and analyze the impact.
- C. Consult with the company's legal department regarding options.
- D. Arrange for additional testing of the product at the testing facility.
Answer: B
NEW QUESTION # 26
A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?
- A. The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
- B. The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
- C. The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.
- D. The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
Answer: B
NEW QUESTION # 27
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
- A. Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
- B. Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
- C. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
- D. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.
Answer: D
NEW QUESTION # 28
During a regulatory authority inspection of a manufacturing site, the inspector observes that one of the medicinal products manufactured at the site is not GMP compliant. The product
Is distributed globally.
Which of the following is the most appropriate action to take FIRST?
- A. Assess the potential safety risk.
- B. Withdraw the affected product from the markets.
- C. Notify the global regulatory authorities.
- D. Send a "Dear Dr." letter to customers.
Answer: C
NEW QUESTION # 29
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
- A. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application.
- B. Request a meeting with the regulatory authority to discuss the application.
- C. Review the regulatory guidelines to determine how to proceed.
- D. Consult with the legal department to discuss the best course of action.
Answer: B
NEW QUESTION # 30
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Reformulate the products with a replacement material.
- B. Complete a gap analysis to identify options.
- C. Review the company's existing Quality Management System
- D. Qualify another supplier and execute a supplier agreement.
Answer: D
NEW QUESTION # 31
You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?
- A. Advise the senior management to send a "Dear Dr." letter.
- B. No action is required since it is an off-label use.
- C. Discuss with regulatory authorities to investigate how to have the off-label indication approved.
- D. File a report to regulatory authorities and advise the marketing department to prevent future off-label use.
Answer: C
NEW QUESTION # 32
A company is developing a line of products for which no ISO standard of performance is available. As a result, the company wishes to propose developing such a standard. Whom should the company contact in order to start the development of the new standard?
- A. The ISO Secretariat
- B. The ISO technical committee in charge of the area
- C. The ISO national member body
- D. The country's regulatory authority
Answer: C
NEW QUESTION # 33
When applying for marketing approval of a drug for a rare disease, which requirement can be waived?
- A. Phase I clinical trials
- B. Phase III clinical trials
- C. Pre-clinical studies
- D. Phase I and II clinical trials
Answer: B
NEW QUESTION # 34
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Individual plasma donation
- B. Product distribution
- C. Plasma fractionation
- D. Plasma pooling
Answer: B
NEW QUESTION # 35
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and records due to confidentiality concerns.
- B. Allow the auditor accompanied access to the room to retrieve the records.
- C. Deny the auditor access to the room and retrieve only the requested records.
- D. Allow the auditor access to the room and records due to the current audit.
Answer: B
NEW QUESTION # 36
A clinical study of a drug is completed to support a marketing approval application.
According to ICH, how long should a sponsor retain the clinical study essential documents?
- A. For a minimum of 10 years after completion of the clinical study
- B. For at least two years after the last approval of an application in an ICH region
- C. Three years after the last clinical study site was supplied with investigational drugs
- D. Until the product has been discontinued from marketing in all ICH regions
Answer: B
NEW QUESTION # 37
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Efficacy and material
- B. Safety and efficacy
- C. Compatibility and safety
- D. Volume and material
Answer: C
NEW QUESTION # 38
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 200 patients for nine months
- B. 100 patients for 12 months
- C. 500 patients for three months
- D. 3.000 total patient exposures
Answer: B
NEW QUESTION # 39
Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?
- A. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product
- B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use
- C. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation
- D. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation
Answer: D
NEW QUESTION # 40
Which of the following is the PRIMARY purpose of an audit report?
- A. To carry out a complete review of product applications
- B. To document compliance history
- C. To define how to prepare new product submissions
- D. To train sales representatives
Answer: B
NEW QUESTION # 41
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Inform the regulatory authorities.
- B. Correct the label text.
- C. Delay the start of product production.
- D. Abort the product launch.
Answer: A
NEW QUESTION # 42
......
New RAC-US Test Materials & Valid RAC-US Test Engine: https://pass4sure.pdfbraindumps.com/RAC-US_valid-braindumps.html